Does North America have a a hard time seeing?
As most of you know, the conventional medical system tends to equate "health" with the absence of symptoms of disease. The entire industry is built around treating symptoms with expensive patented drugs, many of which are profoundly toxic and dangerous. Pharmaceutical companies now rule the entire healthcare system, and they go to great lengths to protect their profits, even if it means sacrificing patients' health in the long run.A recent story from the United Kingdom illustrates how far drug companies will go to make sure their expensive drugs are used when cheaper ones are available, and how medical facilities completely ignore more obvious cost-saving and safe solution.In London, in a legal maneuver intended to eliminate their competition, drug maker Novartis is now trying to force state-run hospitals to use their eye drug, which costs nearly 12 times as much as a cheaper drug the hospitals are currently using. Novartis' drug, Lucentis, is the only one recommended for treatment of macular degeneration in Great Britain. But in an effort to save money, hospitals have been using the cancer drug Avastin instead, even though it's an off-label use that its manufacturer, Roche, says it hasn't even studied. (Avastin was recently recalled by the U.S. FDA because of its dangerous side effects, which include heart attacks..Novartis is now demanding a judicial review, to make the hospitals comply with the standard recommendation to use their drug and stop using Avastin off-label to treat this eye disease. Needless to say, using a dangerous cancer drug off-label to treat macular degeneration is far from an ideal solution, even though it's 12 times cheaper than the other drug alternative... If they really wanted to save money and spare people's eyesight, they'd start paying closer attention to the research into astaxanthin. Studies have shown this safe and natural supplement is therapeutic for macular degeneration, and it's a product anyone can take without running the risk of potentially devastating side effects. Astaxanthin may in fact be one of the most powerful nutrients ever discovered for eye health, and it costs pennies on the dollar compared to either Lucentis or Avastin. Research Supports Astaxanthin for Macular DegenerationWhile the off-label use of Avastin for macular degeneration is said to be based on a study published in The New England Journal of Medicinelast year, which showed Avastin worked just as well as Lucentis for treating macular degeneration, numerous studies exist demonstrating the treatment potential of astaxanthin for this eye disorder.
As most of you know, the conventional medical system tends to equate "health" with the absence of symptoms of disease. The entire industry is built around treating symptoms with expensive patented drugs, many of which are profoundly toxic and dangerous. Pharmaceutical companies now rule the entire healthcare system, and they go to great lengths to protect their profits, even if it means sacrificing patients' health in the long run.A recent story from the United Kingdom illustrates how far drug companies will go to make sure their expensive drugs are used when cheaper ones are available, and how medical facilities completely ignore more obvious cost-saving and safe solution.In London, in a legal maneuver intended to eliminate their competition, drug maker Novartis is now trying to force state-run hospitals to use their eye drug, which costs nearly 12 times as much as a cheaper drug the hospitals are currently using. Novartis' drug, Lucentis, is the only one recommended for treatment of macular degeneration in Great Britain. But in an effort to save money, hospitals have been using the cancer drug Avastin instead, even though it's an off-label use that its manufacturer, Roche, says it hasn't even studied. (Avastin was recently recalled by the U.S. FDA because of its dangerous side effects, which include heart attacks..Novartis is now demanding a judicial review, to make the hospitals comply with the standard recommendation to use their drug and stop using Avastin off-label to treat this eye disease. Needless to say, using a dangerous cancer drug off-label to treat macular degeneration is far from an ideal solution, even though it's 12 times cheaper than the other drug alternative... If they really wanted to save money and spare people's eyesight, they'd start paying closer attention to the research into astaxanthin. Studies have shown this safe and natural supplement is therapeutic for macular degeneration, and it's a product anyone can take without running the risk of potentially devastating side effects. Astaxanthin may in fact be one of the most powerful nutrients ever discovered for eye health, and it costs pennies on the dollar compared to either Lucentis or Avastin. Research Supports Astaxanthin for Macular DegenerationWhile the off-label use of Avastin for macular degeneration is said to be based on a study published in The New England Journal of Medicinelast year, which showed Avastin worked just as well as Lucentis for treating macular degeneration, numerous studies exist demonstrating the treatment potential of astaxanthin for this eye disorder.
This information is brought to you by Dr. Stephen Kelly. Dr. Kelly practices at Family First Chiropractic and Wellness, located at 142 Erickson Drive, Red Deer. Call 403-347-3261 to book an appointement today!
www.family1stchiro.ca
www.family1stchiro.ca